FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a compound of formula (I), as well as a pharmaceutical composition based thereon for inhibiting WEE1 and methods of attenuating or treating cancer or attenuating or treating a malignancy or tumour by inhibiting WEE1.
EFFECT: obtaining new compounds that have the ability to inhibit WEE1 and can be used to treat a disease mediated by this activity.
32 cl, 42 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD FOR PREPARATION AND USE THEREOF | 2020 |
|
RU2828045C2 |
| DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | 2007 |
|
RU2437885C2 |
| BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
| COMPOUNDS FOR INHIBITING KINASE EGFR, METHODS FOR PRODUCTION AND USE THEREOF | 2020 |
|
RU2832925C2 |
| SUBSTITUTED PYRAZOLOPYRIMIDINES AND SUBSTITUTED PURINES AND USE THEREOF AS INHIBITORS OF UBIQUITIN-SPECIFIC PROCESSING PROTEASE 1 (USP1) | 2019 |
|
RU2833222C2 |
| AMINOPYRIMIDINE DERIVATIVES AND USE THEREOF AS AROMATIC HYDROCARBON RECEPTOR MODULATORS | 2021 |
|
RU2826628C1 |
| HPK1 INHIBITORS AND USE THEREOF | 2020 |
|
RU2839132C2 |
| BICYCLIC LACTAMS AND METHODS FOR USE THEREOF | 2016 |
|
RU2716136C2 |
| QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | 2010 |
|
RU2528412C2 |
| MONOACYLGLYCEROL LIPASE MODULATORS | 2019 |
|
RU2797323C2 |
